{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:05:25Z","timestamp":1790373925911,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011117.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000}}],"reference-count":202,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011117.pub3","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T13:37:20Z","timestamp":1662385040000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Opioid agonist treatment for people who are dependent on pharmaceutical opioids"],"prefix":"10.1002","volume":"2022","author":[{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre; Monash University; Frankston Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Chung","family":"Tse","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre; Monash University; Frankston Australia"},{"name":"School of Medicine; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briony","family":"Larance","sequence":"additional","affiliation":[{"name":"School of Psychology, Faculty of the Arts, Social Sciences and Humanities; University of Wollongong; Wollongong Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2362.2003.01218.x","article-title":"Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study","volume":"33","author":"Ahmadi","year":"2003","journal-title":"English Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02915283","article-title":"Controlled trial of maintenance treatment of intravenous buprenorphine dependence","volume":"172","author":"Ahmadi","year":"2005","journal-title":"Irish Journal of Medical Science"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.drugalcdep.2015.07.1005","article-title":"Health service use in a randomized clinical trial comparing three methods of emergency department interventions for opioid dependence","volume":"156","author":"Busch","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD011117.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11606-017-3993-2","article-title":"Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention","volume":"32","author":"D'Onofrio","year":"2017","journal-title":"Journal of General Internal Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011117.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1111\/acem.13203","article-title":"Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after treatment","volume":"24","author":"D'Onofrio","year":"2017","journal-title":"Academic Emergency Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.drugalcdep.2015.07.1062","article-title":"A randomized clinical trial of emergency department initiated treatment for opioid dependence: two and six month outcomes","volume":"156","author":"D'Onofrio","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"16","key":"10.1002\/14651858.CD011117.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D'Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper v maintenance therapy for prescription opioid dependence","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011117.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/ajad.12784","article-title":"Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial","volume":"27","author":"Campbell","year":"2018","journal-title":"American Journal on Addictions"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ajad.13176","article-title":"Examination of correlates of OUD outcomes in young adults: secondary analysis from the XBOT trial","volume":"30","author":"Fishman","year":"2021","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"106514","DOI":"10.1016\/j.addbeh.2020.106514","article-title":"Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among Black adults","volume":"110","author":"Haeny","year":"2020","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2020.01.016","article-title":"Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids","volume":"112","author":"Harvey","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"108221","DOI":"10.1016\/j.drugalcdep.2020.108221","article-title":"Health-related quality of life and opioid use disorder pharmacotherapy: a secondary analysis of a clinical trial","volume":"215","author":"Jalali","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"108422","DOI":"10.1016\/j.drugalcdep.2020.108422","article-title":"An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: a per-protocol and completers analysis","volume":"219","author":"Mitchell","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"108489","DOI":"10.1016\/j.jsat.2021.108489","article-title":"Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: secondary analysis from the National Drug Abuse Treatment Clinical Trials Network","volume":"130","author":"Montgomery","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1111\/add.15531","article-title":"Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis","volume":"116","author":"Murphy","year":"2021","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0020|cit20","first-page":"248","article-title":"Co-occurring depression in patients with opioid use disorder: prevalence and response during treatment with buprenorphine-naloxone or extended-release naltrexone","volume":"30","author":"Na","year":"2021","journal-title":"American Journal on Addictions"},{"issue":"7","key":"10.1002\/14651858.CD011117.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/appi.ajp.2020.20060816","article-title":"Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: potential utility of patient characteristics in guiding choice of treatment","volume":"178","author":"Scodes","year":"2021","journal-title":"American Journal of Psychiatry"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD011117.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1016\/j.biopsych.2020.02.694","article-title":"Depression and suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone","volume":"87","author":"Rizk","year":"2020","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/acer.14729","article-title":"Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial","volume":"45","author":"Roache","year":"2021","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011117.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1038\/npp.2017.263","article-title":"Comparative effectiveness of extended-release naltrexone vs. buprenorphine for opioid dependence treatment-NIDA CTN-0051","volume":"43","author":"Rotrosen","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"109031","DOI":"10.1016\/j.drugalcdep.2021.109031","article-title":"Optimizing opioid use disorder treatment with naltrexone or buprenorphine","volume":"228","author":"Rudolph","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"107649","DOI":"10.1016\/j.drugalcdep.2019.107649","article-title":"Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone","volume":"205","author":"Ruglass","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"108292","DOI":"10.1016\/j.jsat.2021.108292","article-title":"Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure","volume":"124","author":"Shulman","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"Neumann","year":"2013","journal-title":"Journal of Addictive Diseases"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","article-title":"Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction","volume":"38","author":"Neumann","year":"2019","journal-title":"Journal of Addictive Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00952990.2017.1420795","article-title":"Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate","volume":"44","author":"Crist","year":"2018","journal-title":"American Journal of Drug and Alcohol"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","article-title":"Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: results from a multisite randomized trial of adults with opioid use disorder","volume":"106","author":"Evans","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1002\/14651858.CD011117.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/add.14620","article-title":"Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder","volume":"114","author":"Evans","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/add.15594","article-title":"Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial","volume":"117","author":"Hser","year":"2022","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/j.drugalcdep.2015.07.375","article-title":"Intrinsic clustering of treatment outcome in recovery from opioid use disorder: results from starting treatment with agonist","volume":"156","author":"Luo","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2015.10.009","article-title":"Short term health-related quality of life improvement during opioid agonist treatment","volume":"157","author":"Nosyk","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s10900-015-0016-2","article-title":"Risk factors associated with HCV among opioid-dependent patients in a multisite study","volume":"40","author":"Schulte","year":"2015","journal-title":"Journal of Community Health"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/ADM.0000000000000630","article-title":"Secondary analysis of pain outcomes in a large pragmatic randomized trial of buprenorphine\/naloxone versus methadone for opioid use disorder","volume":"14","author":"Shulman","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11481-018-9801-x","article-title":"Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine\/naloxone in a multi-site trial","volume":"13","author":"Zhu","year":"2018","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"108996","DOI":"10.1016\/j.drugalcdep.2021.108996","article-title":"Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: results from a multisite trial of buprenorphine-naloxone and methadone","volume":"228","author":"Zhu","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ajad.12887","article-title":"Changes in psychiatric symptoms and opioid use during buprenorphine\/naloxone treatment in opioid-dependent youth","volume":"28","author":"Hammond","year":"2019","journal-title":"American Journal on Addictions"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/ADM.0000000000000861","article-title":"Therapy dose mediates the relationship between buprenorphine\/naloxone and opioid treatment outcomes in youth receiving medication for opioid use disorder treatment","volume":"16","author":"Hammond","year":"2021","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1097\/ADM.0000000000000224","article-title":"Presence\/absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence","volume":"10","author":"Pecoraro","year":"2016","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/ADM.0000000000000176","article-title":"Presence or absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence","volume":"10","author":"Poole","year":"2016","journal-title":"Journal of Addiction Medicine"},{"issue":"17","key":"10.1002\/14651858.CD011117.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1300\/J069v13n03_04","article-title":"A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification","volume":"13","author":"Amass","year":"1994","journal-title":"Journal of Addictive Diseases"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1360-0443.2007.01935.x","article-title":"Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status","volume":"102","author":"Anglin","year":"2007","journal-title":"Addiction"},{"issue":"8","key":"10.1002\/14651858.CD011117.pub3-BIB0049|cit49","first-page":"92","article-title":"Patients more likely to engage in treatment at 30 days when given buprenorphine in the ED, referred for follow-up","volume":"27","year":"2015","journal-title":"ED Management"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/CXA.0000000000000013","article-title":"Opioids on trial: a systematic review of interventions for the treatment and prevention of opioid overdose","volume":"9","author":"Bahji","year":"2018","journal-title":"Canadian Journal of Addiction"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0051|cit51","first-page":"138","article-title":"A controlled trial of methadone treatment: preliminary analysis of effects on medical care utilization","volume":"17","author":"Batki","year":"1998","journal-title":"Journal of Addictive Diseases"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2017.05.006","article-title":"Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia","volume":"59","author":"Bazazi","year":"2017","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2017.11.023","article-title":"A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12 months post-release","volume":"184","author":"Brinkley-Rubinstein","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1211\/ijpp.14.4.0003","article-title":"Pilot randomised controlled trial of community pharmacy administration of buprenorphine versus methadone","volume":"14","author":"Cameron","year":"2006","journal-title":"International Journal of Pharmacy Practice"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/15284336.2019.1603433","article-title":"Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia","volume":"20","author":"Chandra","year":"2019","journal-title":"HIV Research & Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1037\/a0016597","article-title":"Buprenorphine medication versus voucher contingencies in promoting abstinence from opioids and cocaine","volume":"17","author":"Chopra","year":"2009","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"109077","DOI":"10.1016\/j.drugalcdep.2021.109077","article-title":"Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease","volume":"228","author":"Cook","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0058|cit58","first-page":"S114","article-title":"Buprenorphine initiation and linkage to outpatient buprenorphine treatment does not reduce frequency of injection drug use for inpatient opioid-dependent injection drug users: results of a randomized clinical trial","volume":"30","author":"Cushman","year":"2015","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2016.06.003","article-title":"Buprenorphine initiation and linkage to outpatient buprenorphine do not reduce frequency of injection opiate use following hospitalization","volume":"68","author":"Cushman","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011117.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000052034","article-title":"Comparison of buprenorphine and methadone maintenance in opiate addicts","volume":"4","author":"Eder","year":"1998","journal-title":"European Addiction Research"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","article-title":"Buprenorphine versus methadone maintenance for the treatment of opioid dependence","volume":"94","author":"Fischer","year":"1999","journal-title":"Addiction"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s001150050514","article-title":"Buprenorphine vs methadone maintenance treatment for opioid dependence","volume":"70","author":"Fischer","year":"1999","journal-title":"Nervenarzt"},{"issue":"10","key":"10.1002\/14651858.CD011117.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0065|cit65","first-page":"1","article-title":"Superiority of buprenorphine over suboxone in preventing addiction relapse in opioid addicts under maintenance therapy: a double-blind clinical trial","volume":"7","author":"Ghalehney","year":"2018","journal-title":"Asia Pacific Journal of Medical Toxicology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2016.11.037","article-title":"A randomized clinical trial of buprenorphine for prisoners: findings at 12-months post-release","volume":"172","author":"Gordon","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.drugalcdep.2018.04.010","article-title":"Initiating buprenorphine treatment prior to versus after release from prison: arrest outcomes","volume":"188","author":"Gordon","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cct.2019.02.009","article-title":"A randomized controlled trial of buprenorphine for probationers and parolees: bridging the gap into treatment","volume":"79","author":"Gordon","year":"2019","journal-title":"Contemporary Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0376-8716(00)00211-8","article-title":"Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study","volume":"62","author":"Gossop","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2007.11.021","article-title":"A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification","volume":"94","author":"Gruber","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"10173","key":"10.1002\/14651858.CD011117.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0072|cit72","first-page":"147","article-title":"Better efficacy of buprenorphine and methadone in opioid dependence. Requirements for abstinence from non-opioids before starting treatment paid off","volume":"111","author":"Hoffmann","year":"2014","journal-title":"Lakartidningen"},{"issue":"20","key":"10.1002\/14651858.CD011117.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug and Alcohol Dependence."},{"issue":"18","key":"10.1002\/14651858.CD011117.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1037\/1064-1297.13.4.293","article-title":"Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence","volume":"13","author":"Marsch","year":"2005","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"9358","key":"10.1002\/14651858.CD011117.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/10826088209056328","article-title":"Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study","volume":"17","author":"Karp-Gelernter","year":"1982","journal-title":"International Journal of the Addictions"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"108006","DOI":"10.1016\/j.jsat.2020.108006","article-title":"Impact of methadone treatment initiated in jail on subsequent arrest","volume":"113","author":"Kelly","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.drugalcdep.2015.09.019","article-title":"Predictors of outcome from computer-based treatment for substance use disorders: results from a randomized clinical trial","volume":"157","author":"Kim","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ijnp\/pyaa069","article-title":"A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder","volume":"24","author":"Kranzler","year":"2021","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0082|cit82","first-page":"148","article-title":"Buprenorphine and methadone to opiate addicts \u2013 a randomized trial","volume":"125","author":"Kristensen","year":"2005","journal-title":"Tidsskrift for den Norske Laegeforening"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-016-0061-1","article-title":"Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)","volume":"17","author":"Kun\u00f8e","year":"2016","journal-title":"BMC Pharmacology and Toxicology"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0084|cit84","first-page":"328","article-title":"Predictors of retention in treatment for opioid use disorder following administration of RBP-6000 vs. placebo","volume":"27","author":"Laffont","year":"2018","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ajad.12859","article-title":"No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: a 3-month randomized study and 9-month open-treatment follow-up study","volume":"28","author":"Latif","year":"2019","journal-title":"American Journal on Addictions"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study","volume":"76","author":"Latif","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0087|cit87","first-page":"S108","article-title":"Initiating buprenorphine maintenance for opiate-dependent hospitalized patients: a randomized controlled trial","volume":"28","author":"Liebschutz","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0090|cit90","first-page":"S266","article-title":"Buprenorphine implants for the treatment of opioid dependence: six and 12 month outcomes","volume":"38","author":"Beebe","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011117.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1360-0443.2005.01122.x","article-title":"Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use","volume":"100","author":"Longshore","year":"2005","journal-title":"Addiction"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0094|cit94","first-page":"212","article-title":"Buprenorphine vs methadone: an Italian multicenter study","volume":"13","author":"Maremmani","year":"1999","journal-title":"Giornale Italiano di Farmacia Clinica"},{"issue":"8","key":"10.1002\/14651858.CD011117.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08897077.2011.609446","article-title":"A randomized trial of methadone initiation prior to release from incarceration","volume":"33","author":"McKenzie","year":"2012","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/add.13259","article-title":"Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine\/naloxone and naltrexone maintenance treatment","volume":"111","author":"Mokri","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clpt.2003.09.004","article-title":"Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence","volume":"75","author":"Montoya","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0099|cit99","first-page":"S50","article-title":"Exposure-response analyses to support dosing recommendations for RBP-6000 buprenorphine monthly formulation in subjects with opioid use disorder","volume":"44","author":"Ngaimisi","year":"2017","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"108532","DOI":"10.1016\/j.drugalcdep.2021.108532","article-title":"Within-subject evaluation of interim buprenorphine treatment during waitlist delays","volume":"220","author":"Oleskowicz","year":"2021","journal-title":"Drug and Alcohol Dependence\u00a0"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2014.10.003","article-title":"Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia","volume":"50","author":"Piralishvili","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0103|cit103","first-page":"291A","article-title":"Buprenorphine maintenance vs. placebo for opioid dependence","volume":"95","author":"Raleigh","year":"2017","journal-title":"American Family Physician"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1360-0443.2011.03463.x","article-title":"Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial","volume":"106","author":"Reimer","year":"2011","journal-title":"Addiction"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/j.1360-0443.2006.01603.x","article-title":"Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial","volume":"101","author":"Robertson","year":"2006","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"10","key":"10.1002\/14651858.CD011117.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jama.283.10.1303","article-title":"Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial","volume":"283","author":"Sees","year":"2000","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0108|cit108","first-page":"202","article-title":"Attrition from a randomized trial comparing psychosocial treatments in a 180-day methadone detoxification clinic","volume":"132","author":"Sees","year":"1993","journal-title":"NIDA Research Monograph Series"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/QAI.0000000000001683","article-title":"Risky sexual behavior among individuals receiving buprenorphine\/naloxone opiate dependency treatment: HIV prevention trials network (HPTN) 058","volume":"78","author":"Shava","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.drugalcdep.2015.07.550","article-title":"Interim buprenorphine treatment: leveraging technology to bridge waitlist delays","volume":"156","author":"Sigmon","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"25","key":"10.1002\/14651858.CD011117.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"New England journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011117.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/add.14278","article-title":"Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial","volume":"113","author":"Solli","year":"2018","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011117.pub3-BIB0114|cit114","first-page":"15","article-title":"The effectiveness of injectable extended release naltrexone versus daily buprenorphine-naloxone for opioid dependence: a randomized clinical trial","volume":"90","author":"Solli","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011117.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000501931","article-title":"Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: extension of a randomized clinical trial","volume":"25","author":"Solli","year":"2019","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/add.14737","article-title":"Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial","volume":"115","author":"Stein","year":"2020","journal-title":"Addiction"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0376-8716(83)90068-6","article-title":"Treatment outcome in methadone detoxification: relationship to initial levels of illicit opiate use","volume":"12","author":"Stitzer","year":"1983","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","article-title":"Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index","volume":"16","author":"Strain","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011117.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1046\/j.1360-0443.2000.951116314.x","article-title":"Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome","volume":"95","author":"Strang","year":"2000","journal-title":"Addiction"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1037\/pha0000199","article-title":"Interim buprenorphine treatment during delays to comprehensive treatment: changes in psychiatric symptoms","volume":"26","author":"Streck","year":"2018","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011117.pub3-BIB0122|cit122","first-page":"S61","article-title":"Effectiveness of extended release naltrexone versus daily buprenorphine-naloxone for opioid dependence-Norway trial","volume":"43","author":"Tanum","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.drugalcdep.2016.08.548","article-title":"Optimal prevention of relapse among opioid users: a 12-week randomized controlled trial of extended-release naltrexone injections versus daily buprenorphine-naloxone","volume":"171","author":"Tanum","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"\u00a09 Suppl","key":"10.1002\/14651858.CD011117.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/j.biopsych.2018.02.1165","article-title":"The effectiveness of injectable extended release naltrexone versus daily buprenorphine-naloxone for opioid dependence in short and long term treatment","volume":"83","author":"Tanum","year":"2018","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0125|cit125","first-page":"530","article-title":"\"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial\": correction","volume":"75","author":"Tanum","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011117.pub3-BIB0126|cit126","first-page":"28","article-title":"Use of benzodiazepines among opioid dependent individuals during a 12 week randomized study and a 36-week follow-up study with extended release naltrexone","volume":"20","author":"Tanum","year":"2018","journal-title":"Heroin Addiction and Related Clinical Problems"},{"issue":"Suppl","key":"10.1002\/14651858.CD011117.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/j.biopsych.2019.03.535","article-title":"No increase in chronic pain among opioid-dependent individuals randomized to treatment with extended-release naltrexone compared to buprenorphine-naloxone","volume":"85","author":"Tanum","year":"2019","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011117.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/archinte.1982.00340230087016","article-title":"Outpatient treatment of prescription opioid dependence: comparison of two methods","volume":"142","author":"Rawson","year":"1982","journal-title":"Archives of Internal Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD011117.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000052036","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study","volume":"4","author":"Uehlinger","year":"1998","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"e12344","DOI":"10.1111\/appy.12344","article-title":"Treatment of opioid dependence with buprenorphine\/naloxone sublingual tablets: a phase 3 randomized, double-blind, placebo-controlled trial","volume":"11","author":"Wang","year":"2019","journal-title":"Asia-Pacific Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011117.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jamainternmed.2017.3947","article-title":"Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial","volume":"177","author":"Watkins","year":"2017","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011117.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence","volume":"68","author":"Weiss","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"108241","DOI":"10.1016\/j.jsat.2020.108241","article-title":"A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail","volume":"128","author":"Gordon","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Seval N Frank CA Litwin AH Roth P Schade MA Pavlicova M Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder Contemporary Clinical Trials 2021 105 106394 dx.doi.org\/10.1016\/j.cct.2021.106394","DOI":"10.1016\/j.cct.2021.106394"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","article-title":"The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale","volume":"69","author":"Socias","year":"2018","journal-title":"Contemporary Clinical Trials"},{"issue":"1-2","key":"10.1002\/14651858.CD011117.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0376-8716(99)00074-5","article-title":"Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet","volume":"58","author":"Amass","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0139|cit139","unstructured":"Australian Institute of Health and Welfare Opioid harm in Australia: and comparisons between Australia and Canada, 2018 nla.gov.au\/nla.obj-2312926122\/view"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1360-0443.2009.02538.x","article-title":"Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users","volume":"104","author":"Banta-Green","year":"2009","journal-title":"Addiction"},{"issue":"6","key":"10.1002\/14651858.CD011117.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"The opioid crisis in Canada: a national perspective","volume":"38","author":"Belzak","year":"2018","journal-title":"Health Promotion and Chronic Disease Prevention in Canada : Research, Policy and Practice"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2003.10.012","article-title":"Prescription opioid abuse in patients presenting for methadone maintenance treatment","volume":"73","author":"Brands","year":"2004","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ : Canadian Medical Association Journal"},{"issue":"9","key":"10.1002\/14651858.CD011117.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/pme.12773","article-title":"Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort","volume":"16","author":"Campbell","year":"2015","journal-title":"Pain Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10826089609045806","article-title":"Methadone maintenance and addicts' risk of fatal heroin overdose","volume":"31","author":"Caplehorn","year":"1996","journal-title":"Substance Use & Misuse"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejp.1291","article-title":"Prescription opioid analgesic use in France: trends and impact on morbidity\u2013mortality","volume":"23","author":"Chenaf","year":"2019","journal-title":"European Journal of Pain"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002210","article-title":"LAAM maintenance vs methadone maintenance for heroin dependence","author":"Clark","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0149|cit149","unstructured":"Cleeland C The Brief Pain Inventory (BPI), 1991 www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.annemergmed.2019.04.019","article-title":"Risk factors for misuse of prescribed opioids: a systematic review and meta-analysis","volume":"74","author":"Cragg","year":"2019","journal-title":"Annals of Emergency Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0151|cit151","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0152|cit152","unstructured":"Degenhardt L Larance B Mathers B Azim T Kamarulzaman A Mattick R Reference Group to the United Nations on HIV and Injecting Drug Use Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV www.unodc.org\/documents\/hiv-aids\/publications\/Benefits_and_risks_of_pharmaceutical_opioids.pdf"},{"issue":"1-2","key":"10.1002\/14651858.CD011117.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"10208","key":"10.1002\/14651858.CD011117.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0155|cit155","unstructured":"Ellerstrand J Ferrari A Degenhardt L Whiteford H Leung J A systematic review of the global prevalence of prescription opioid non-medical use with an estimate of prescription opioid dependence. NDARC Technical Report No. 337 ndarc.med.unsw.edu.au\/resource\/systematic-review-global-prevalence-prescription-opioid-non-medical-use-estimate"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002208","article-title":"Methadone maintenance at different dosages for opioid dependence","author":"Faggiano","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/09595230801956124","article-title":"Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users","volume":"27","author":"Fischer","year":"2008","journal-title":"Drug and Alcohol Review"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011117.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"ES191","DOI":"10.36076\/ppj.2012\/15\/ES191","article-title":"Prescription opioid related misuse, harms, diversion and interventions in Canada: a review","volume":"15","author":"Fischer","year":"2012","journal-title":"Pain Physician"},{"issue":"8","key":"10.1002\/14651858.CD011117.pub3-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004145.pub4","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","author":"Gowing","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"e6425","DOI":"10.1136\/bmj.e6425","article-title":"The role of opioid substitution treatment in reducing HIV transmission","volume":"345","author":"Gowing","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2471\/BLT.12.109553","article-title":"Mitigating the risk of HIV infection with opioid substitution treatment","volume":"91","author":"Gowing","year":"2013","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"The GRADE working group","year":"2004","journal-title":"BMJ"},{"issue":"2-3","key":"10.1002\/14651858.CD011117.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2011.04.004","article-title":"30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California","volume":"118","author":"Grella","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"issue":"7560","key":"10.1002\/14651858.CD011117.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0166|cit166","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0167|cit167","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","article-title":"A 33-year follow-up of narcotics addicts","volume":"58","author":"Hser","year":"2001","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1017\/S0033291702006074","article-title":"Short screening scales to monitor population prevalences and trends in non-specific psychological distress","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"e193365","DOI":"10.1001\/jamanetworkopen.2019.3365","article-title":"Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review","volume":"2","author":"Klimas","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"e025799","DOI":"10.1136\/bmjopen-2018-025799","article-title":"Slow release oral morphine versus methadone for the treatment of opioid use disorder","volume":"9","author":"Klimas","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/add.14784","article-title":"Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018","volume":"115","author":"Lam","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamapsychiatry.2019.4170","article-title":"All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis","volume":"77","author":"Larney","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0174|cit174","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0175|cit175","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0176|cit176","volume-title":"Manual for Depression and Anxiety Stress Scales","author":"Lovibond","year":"1995"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0177|cit177","first-page":"E671","article-title":"Prevalence of pain among non-medical prescription opioid users in substance use treatment populations: systematic review and meta-analyses","volume":"16","author":"Lusted","year":"2013","journal-title":"Pain Physician"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0178|cit178","first-page":"e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0179|cit179","unstructured":"Man N Chrzanowska A Sutherland R Degenhardt L Peacock A Trends in drug-related hospitalisations in Australia, 1999\u20132019. Drug Trends Bulletin Series ndarc.med.unsw.edu.au\/resource-analytics\/trends-drug-related-hospitalisations-australia-1999-2019 doi.org\/10.26190\/qwad-0v25"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011117.pub3-BIB0181|cit181","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths \u2013 United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/10826084.2013.800112","article-title":"Engagement, retention, and abstinence for three types of opioid users in Florida","volume":"48","author":"McCabe","year":"2013","journal-title":"Substance Use & Misuse"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients","volume":"22","author":"Moore","year":"2007","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0186|cit186","first-page":"363","article-title":"Characteristics of a non-treatment seeking sample of over-the-counter codeine users: implications for intervention and prevention","volume":"7","author":"Nielsen","year":"2011","journal-title":"Journal of Opioid Management"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ADM.0b013e318277e92e","article-title":"A comparison of buprenorphine taper outcomes between prescription opioid and heroin users","volume":"7","author":"Nielsen","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.drugalcdep.2015.02.004","article-title":"Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011","volume":"149","author":"Nielsen","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jsat.2014.06.006","article-title":"Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users","volume":"48","author":"Nielsen","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011117.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/medicina43030029","article-title":"Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania","volume":"43","author":"Padaiga","year":"2007","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0191|cit191","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0192|cit192","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pain.2008.06.025","article-title":"Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials","volume":"139","author":"Turk","year":"2008","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD011117.pub3-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13011-017-0120-7","article-title":"Chronic pain and opioid misuse: a review of reviews","volume":"12\u00a0","author":"Voon","year":"2017","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"4","key":"10.1002\/14651858.CD011117.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0199|cit199","volume-title":"WHOQOL: Measuring Quality of Life","author":"World Health Organization","year":"1997"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0200|cit200","unstructured":"World Health Organization ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2004 apps.who.int\/iris\/handle\/10665\/42980"},{"key":"10.1002\/14651858.CD011117.pub3-BIB0201|cit201","volume-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organization","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD011117.pub3-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117.pub2","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"Nielsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T08:33:34Z","timestamp":1703666014000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011117.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Drugs and Alcohol Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":202,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011117.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}